Skip to main content
Publications
Hoyo C, Schildkraut JM, Murphy SK, Chow WH, Vaughan TL, Risch H, Marks JR, Jirtle RL, Calingaert B , Mayne S, Fraumeni, Jr. J, Gammon MD. IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas . Int J Cancer. 2009 Dec 1;125(11):2673-8.
Acquavella J, Weinhandl E, Bradbury B, Brookhart A, Sturmer T, Rothman KJ . Confounding by indication studying epoetin and mortality . Poster presented at the 25th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2009. Providence, RI. [abstract] Pharmacoepidemiol Drug Saf. 2009 Aug 16; 18(Suppl 1):S28.
Becker N, Fortuny J , Alvaro T, Nieters A, Maynadie M, Foretova L, Staines A, Brennan P, Boffetta P, Cocco PL, de Sanjose S. Medical history and risk of lymphoma: results of a European case-control study (EPILYMPH) . J Cancer Res Clin Oncol. 2009 Aug;135(8):1099-107. doi: 10.1007/s00432-009-0551
Villanueva CM, Silverman DT, Malats N, Tardon A, Garcia-Closas R, Serra C, Carrato A, Fortuny J , Rothman N, Dosemeci M, Kogevinas M. Determinants of quality of interview and impact on risk estimates in a case-control study of bladder cancer . Am J Epidemiol. 2009 Jul 15;170(2):237-43. doi: 10.1093/aje/kwp136
Martinez-Fernandez A, Garcia-Albeniz X , Pineda E, Visa L, Gallego R, Codony-Servat J, Auge JM, Longaron R, Gascon P, Lacy A, Castells A, Maurel J. Serum matrilysin levels predict outcome in curatively resected colorectal cancer patients . Ann Surg Oncol. 2009 May;16(5):1412-20. doi: 10.1245/s10434-009-0405-9
Schildkraut JM, Goode EL, Clyde MA, Iversen ES, Moorman PG, Berchuck A, Marks JR, Lissowska J, Brinton L, Peplonska B, Cunningham JM, Vierkant RA, Rider DN, Chenevix-Trench G, Webb PM, Beesley J, Chen X, Phelan C, Sutphen R, Sellers TA, Pearce L, Wu AH, Den Berg DV, Conti D, Elund CK, Anderson R, Goodman MT, Lurie G, Carney ME, Thompson PJ, Gayther SA, Ramus SJ, Jacobs I, Kjaer SK, Hogdall E, Blaakaer J, Hogdall C, Easton DF, Song H, Pharoah HDP, Whittemore AS, McGuire V, Quaye L, Anton-Culver H, Ziogas A, Terry KL, Cramer DW, Hankinson SE, Tworoger SS, Calingaert B , Chanock S, Sherman M, Garcia-Closas M. Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer . Cancer Res. 2009 Mar;69(6):2349-57.
Gallego R, Codony-Servat J, Garcia-Albeniz X , Carcereny E, Longaron R, Oliveras A, Tosca M, Auge JM, Gascon P, Maurel J. Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer . Endocr Relat Cancer. 2009 Mar;16(1):311-7. doi: 10.1677/ERC-08-0250
Fortuny J , Kogevinas M, Garcia-Closas M, Real FX, Tardon A, Garcia-Closas R, Serra C, Carrato A, Lloreta J, Rothman N, Villanueva C, Dosemeci M, Malats N, Silverman D. Use of analgesics and nonsteroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain . Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1696-702. doi: 10.1158/1055-9965.EPI-06-0038
Richards DA, Boehm KA, Waterhouse DM, Wagener DJ, Krishnamurthi SS, Rosemurgy A, Grove W, Macdonald K, Gulyas S, Clark MJ , Dasse KD. Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study . Ann Oncol. 2006 Jul 1;17:1096-102.